Dr. Sagar A. Patel, MD
Claim this profileEmory Saint Joseph's Hospital
Area of expertise
Prostate Cancer
Sagar A. Patel, MD has run 2 trials for Prostate Cancer. Some of their research focus areas include:
Myelofibrosis
Sagar A. Patel, MD has run 1 trial for Myelofibrosis.
Affiliated Hospitals
Emory Saint Joseph's Hospital
Emory University Hospital Midtown
Clinical Trials Sagar A. Patel, MD is currently running
Relugolix + Abiraterone Acetate vs Leuprolide + Abiraterone Acetate
for Prostate Cancer
This phase III/IV trial compares the impact of leuprolide and abiraterone acetate (AA) versus relugolix and AA on the heart in hormone-naive patients with advanced prostate cancer receiving pelvic radiation therapy. Leuprolide is in a class of medications called gonadotropin-releasing hormone agonists (GNRHa). It prevents the body from making luteinizing hormone-releasing hormone (LHRH) and luteinizing hormone (LH). This causes the testicles to stop making testosterone (a male hormone) in men and may stop the growth of prostate tumor cells that need testosterone to grow. Abiraterone acetate, an androgen biosynthesis inhibitor, works by decreasing the amount of certain hormones in the body. Relugolix, a GNRH antagonist, works by decreasing the amount of testosterone produced by the body. This may slow or stop the spread of prostate tumor cells that need testosterone to grow. The use of hormone therapy with radiation therapy has been shown to improve survival, however, studies have suggested that the addition of hormone therapy may worsen heart (cardiac) disease and high blood pressure. In fact, studies have shown that the most common cause of death in prostate cancer patients is due to heart disease or heart attacks. Computed tomography (CT) scans create a series of detailed pictures of areas inside the body; the pictures are created by a computer linked to an x-ray machine. In this study, sophisticated cardiac CT images are used to take pictures of patients' heart and coronary arteries to help assess damage to the heart. Using cardiac CT and blood tests, this trial may help doctors determine which patients are at risk of cardiac disease when treated with combination hormone therapy, as well as the differential risk of leuprolide versus relugolix in combination with abiraterone acetate.
Recruiting
2 awards
Phase 3
5 criteria
Hormone Therapy + Radiation
for Prostate Cancer
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Recruiting
2 awards
Phase 3
1 criteria
More about Sagar A. Patel, MD
Clinical Trial Related
1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Sagar A. Patel, MD has experience with
- Leuprolide
- Relugolix
- Abiraterone Acetate
- Radiation Therapy
- Pegylated Interferon Alfa-2a
- Photon
Breakdown of trials Sagar A. Patel, MD has run
Prostate Cancer
Myelofibrosis
Breast Cancer
Prostate Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sagar A. Patel, MD specialize in?
Sagar A. Patel, MD focuses on Prostate Cancer and Myelofibrosis. In particular, much of their work with Prostate Cancer has involved Stage I patients, or patients who are Stage II.
Is Sagar A. Patel, MD currently recruiting for clinical trials?
Yes, Sagar A. Patel, MD is currently recruiting for 3 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Sagar A. Patel, MD has studied deeply?
Yes, Sagar A. Patel, MD has studied treatments such as Leuprolide, Relugolix, Abiraterone Acetate.
What is the best way to schedule an appointment with Sagar A. Patel, MD?
Apply for one of the trials that Sagar A. Patel, MD is conducting.
What is the office address of Sagar A. Patel, MD?
The office of Sagar A. Patel, MD is located at: Emory Saint Joseph's Hospital, Atlanta, Georgia 30342 United States. This is the address for their practice at the Emory Saint Joseph's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.